Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer

Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its relationship to molecularly defined subsets, we analyzed BGN expression by immunohistochemistry on a tissue microarray c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neoplasia
Main Authors: Jacobsen, Frank, Kraft, Juliane, Schroeder, Cornelia, Hube-Magg, Claudia, Kluth, Martina, Lang, Dagmar S., Simon, Ronald, Sauter, Guido, Izbicki, Jakob R., Clauditz, Till S., Luebke, Andreas M., Hinsch, Andrea, Wilczak, Waldemar, Wittmer, Corinna, Büscheck, Franziska, Höflmayer, Doris, Minner, Sarah, Tsourlakis, Maria Christina, Huland, Hartwig, Graefen, Markus, Budäus, Lars, Thederan, Imke, Salomon, Georg, Schlomm, Thorsten, Melling, Nathaniel
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press 2017
Assuntos:
Original article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5565634/
https://ncbi.nlm.nih.gov/pubmed/28830008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2017.06.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados